Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis.

20 In Japan, a regional population‐based cancer registry study that included data for 1995–2018 showed a trend of improvement in the survival rate for patients with AGC over time. 21 Furthermore, a single‐institution retrospective study that included data for 2007–2018 found that OS in patients with AGC was prolonged across different time periods when adjusted for prognostic factors. 22 Few patients in these studies received nivolumab because it was not approved in Japan until 2017.

also in 53,322 other papers